Prolonged complete response after GEMOX chemotherapy in a patient with advanced fibrolamellar hepatocellular carcinoma

Case Reports in Oncology

Volumn 5, Issue 1, 2012, Pages 169-172

  Gras, Pauline ^a   Truant, Stéphanie ^a   Boige, Valérie ^b   Ladrat, Laure ^a   Rougier, Philippe ^c   Pruvot, François René ^b   Hebbar, Mohamed ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Fibrolamellar hepatocellular carcinoma; Gemcitabine; Healthy liver; Oxaliplatin

Indexed keywords

GEMCITABINE; OXALIPLATIN;

ADULT; ADVANCED CANCER; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER SURGERY; CASE REPORT; CELIAC GANGLION; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; FEMALE; FIBROLAMELLAR HEPATOCELLULAR CARCINOMA; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER HISTOLOGY; LIVER RESECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MEDIASTINUM LYMPH NODE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; PARAAORTIC LYMPH NODE; PRIMARY TUMOR; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 84860779811     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000338242     Document Type: Article

References (14)

1. Ward SC, Waxman S: Fibrolamellar carcinoma: a review with focus on genetics and comparison to other malignant primary liver tumors. Semin Liver Dis 2011;31:61-70.
2. Katzenstein HM, Krailo MD, Malogolowkin MH, Ortega JA, Qu W, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Newman K, Finegold MJ, Haas JE, Sensel MG, Castleberry RP, Bowman LC: Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer 2003;97:2006-2012.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
4. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
5. Trevisani F, Frigerio M, Santi V, Grignashi A, Bernardi M: Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis 2010;42:341-347.
6. Boige V, Barbare JC, Rosmorduc O: Groupe de travail carcinome hépatocellulaire Prodige-Afef. Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations. Gastroenterol Clin Biol 2008;32:3-7.
7. Mulcahy MF: Management of hepatocellular cancer. Curr Treat Options Oncol 2005;6:423-435.
8. Hebbar M, Ernst O, Cattan S, Dominguez S, Oprea C, Mathurin P, Triboulet JP, Paris JC, Pruvot FR: Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma. Oncology 2006;70:154-158.
9. Romano O, Truant S, Sergent-Baudson G, Comet B, Pruvot FR, Hebbar M: Docetaxel therapy for advanced hepatocellular carcinoma developed in healthy liver: report of three cases. J Chemother 2008;20:518-520.
10. Taïeb J, Bonyhay L, Golli L, Ducreux M, Boleslawski E, Tigaud JM, de Baere T, Mansourbakht T, Delgado MA, Hannoun L, Poynard T, Boige V: Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer 2003;98:2664-2670.
11. Louafi S, Boige V, Ducreux M, Bonyhay L, Mansourbakht T, de Baere T, Asnacios A, Hannoun L, Poynard T, Taïeb J: Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma: results of a phase II study. Cancer 2007;109:1384-1390.
12. Edeline J, Raoul JL, Vauleon E, Guillygomac'h A, Boudjema K, Boucher E: Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study. World J Gastroenterol 2009;15:713-716.
13. Boschetti G, Walter T, Hervieu V, Cassier P, Lombard-Bohas C, Adham M, Scoazec JY, Dumortier J: Complete response of hepatocellular carcinoma with systemic combination chemotherapy: not to get out the chemotherapy? Eur J Gastroenterol Hepatol 2010;22:1015-1018.
14. Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, Leung T, Gansukh B, Saltz LB: Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010;304:2154-2160.